(Z)-4-(4-hydroxy-3-methoxybenzylidene)-3-isopropyl-1-(3-nitrophenyl)-1H-pyrazol-5(4H)-one | 1393580-81-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: (Z)-4-(4-hydroxy-3-methoxybenzylidene)-3-isopropyl-1-(3-nitrophenyl)-1H-pyrazol-5(4H)-one
• 英文别名: (4Z)-4-[(4-hydroxy-3-methoxyphenyl)methylidene]-2-(3-nitrophenyl)-5-propan-2-ylpyrazol-3-one
• CAS: 1393580-81-8
• 化学式: C₂₀H₁₉N₃O₅
• 分子量: 381.388
• InChiKey: LXLZSKMZHMDJFF-SXGWCWSVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  28
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  108
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  香草醛 、 异丁酰乙酸乙酯 、 3-硝基苯肼 反应 0.17h， 以67%的产率得到(Z)-4-(4-hydroxy-3-methoxybenzylidene)-3-isopropyl-1-(3-nitrophenyl)-1H-pyrazol-5(4H)-one
  参考文献：
  名称：

  Discovery and Optimization of 1,3,4-Trisubstituted-pyrazolone Derivatives as Novel, Potent, and Nonsteroidal Farnesoid X Receptor (FXR) Selective Antagonists

  摘要：

  LBVS of 12480 in-house compounds, followed by HTRF assay, resulted in one nonsteroidal compound (11) with antagonistic activity against FXR (69.01 +/- 11.75 mu M). On the basis of 11, 26 new derivatives (12a-z) were designed and synthesized accordingly. Five derivatives (12f-g, 12p, 12u, and 12y) showed better antagonistic activities against FXR than compound 11. Remarkably, the most potent derivative, 12u (8.96 +/- 3.62 mu M), showed antagonistic capability approximately 10 times and 8-fold higher than that of the control (GS) and the starting compound 11, respectively. 12u was further confirmed to have high binding affinity with FXR alpha LBD, FXR specificity over six other nuclear receptors, and potent antagonistic activity against FXR in two cell testing platforms. 12u strongly suppressed the regulating effects of CDCA on FXR target genes. The therapeutic potential of 12u was identified by lowering the contents of triglyceride and cholesterol in human hepatoma HepG2 cells and in the cholesterol-fed C57BL/6 mices.

  DOI：

  10.1021/jm3002718

文献信息

• Discovery and Optimization of 1,3,4-Trisubstituted-pyrazolone Derivatives as Novel, Potent, and Nonsteroidal Farnesoid X Receptor (FXR) Selective Antagonists
  作者：Huang Huang、Ying Yu、Zhenting Gao、Yong Zhang、Chenjing Li、Xing Xu、Hui Jin、Wenzhong Yan、Ruoqun Ma、Jin Zhu、Xu Shen、Hualiang Jiang、Lili Chen、Jian Li

  DOI：10.1021/jm3002718

  日期：2012.8.23

  LBVS of 12480 in-house compounds, followed by HTRF assay, resulted in one nonsteroidal compound (11) with antagonistic activity against FXR (69.01 +/- 11.75 mu M). On the basis of 11, 26 new derivatives (12a-z) were designed and synthesized accordingly. Five derivatives (12f-g, 12p, 12u, and 12y) showed better antagonistic activities against FXR than compound 11. Remarkably, the most potent derivative, 12u (8.96 +/- 3.62 mu M), showed antagonistic capability approximately 10 times and 8-fold higher than that of the control (GS) and the starting compound 11, respectively. 12u was further confirmed to have high binding affinity with FXR alpha LBD, FXR specificity over six other nuclear receptors, and potent antagonistic activity against FXR in two cell testing platforms. 12u strongly suppressed the regulating effects of CDCA on FXR target genes. The therapeutic potential of 12u was identified by lowering the contents of triglyceride and cholesterol in human hepatoma HepG2 cells and in the cholesterol-fed C57BL/6 mices.